4.6 Article

Relationship between mean follow-up intraocular pressure, rates of visual field progression and current target intraocular pressure guidelines

Journal

BRITISH JOURNAL OF OPHTHALMOLOGY
Volume 106, Issue 2, Pages 229-233

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bjophthalmol-2020-317406

Keywords

Glaucoma; Intraocular pressure; Vision; Field of vision

Categories

Funding

  1. National Eye Institute [U10EY14267, EY08208, EY11008, EY019869, EY13959, 1EY027510, EY025253]
  2. Eyesight Foundation of Alabama -Birmingham, AL
  3. Alcon Laboratories Inc. -Fort Worth, TX
  4. Allergan Inc. Dublin, Ireland
  5. Pfizer Inc. -New York, NY
  6. Merck Inc. -Rahway, NJ
  7. Santen Inc. Osaka, Japan
  8. Research to Prevent Blindness, New York, NY (Department of Ophthalmology, Columbia University Medical Center)
  9. Edith C. Blum Foundation, New York, NY
  10. American Glaucoma Society, San Francisco, CA
  11. Research to Prevent Blindness, New York, NY (Department of Ophthalmology, University of California San Diego)

Ask authors/readers for more resources

This study aimed to investigate whether adhering to current guidelines for intraocular pressure (IOP) target can slow the progression of glaucomatous visual field (VF). The results showed that adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease.
Aims To investigate if eyes presenting intraocular pressure (IOP) within the limits of current guideline-driven target IOP indeed experience slow rates of glaucomatous visual field (VF) progression. Methods A total of 8598 24-2 VF tests from 603 eyes from the African Descent and Glaucoma Evaluation Study with manifest glaucoma were included. The sample was split into three groups based on baseline VF mean deviation (MD): G1 (better than -5.0 dB), G2 (-5.0 to -10 dB) and G3 (worse than -10 dB). We investigated the relationship between existing target IOP guidelines and rates of MD progression in these groups. Results For stable eyes, the medians and IQR of the mean follow-up IOP were G1=15.0 mmHg (IQR: 13.1 to 17.7), G2=13.2 mmHg (IQR: 11.6 to 14.3) and G3=11.9 mmHg (IQR: 10.1 to 13.8) (p<0.01). When considering the mean follow-up IOP within the limits proposed by current guidelines, the median MD slopes were: -0.20 dB/y (IQR: -0.43 to -0.02) for G1<21 mmHg, -0.19 dB/y (IQR: -0.51 to -0.01) for G2<18 mmHg and -0.15 dB/y (IQR: -0.47 to 0.05) for G3<15 mmHg (p=0.63). There were no significant differences between racial groups. Conclusion In a sample of patients with manifest glaucoma, despite substantial variability between eyes, adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available